Nebula Biocides
Key Facts
| Invested since | 2021 |
| Based in | Mecklenburg-Western Pomerania |
About the company
Nebula Biocides GmbH was founded in 2019 as a spin-off from the Leibniz Institute for Plasma Science and Technology (INP) by the scientists Dr. Jörn Winter, Dr. Ansgar Schmidt-Bleker and the director of INP Prof. Dr. Klaus-Dieter Weltmann. With the aim of providing comprehensive protection against infectious pathogens, the company develops application-oriented disinfection solutions that reliably kill not only bacteria and viruses but also persistent bacterial spores.
Do you want to
know more about this company?
Nebula Biocides in the news
More startups from Life Sciences
Zedira is a clinical stage biotech company specialized in the enzyme class of transglutaminases. Zedira performs drug discovery (e.g. celiac disease, diabetic nephropathy and thromboprophylaxis) and markets specialty reagents for …
To the complete profileof Zedira
Aignostics, a spin-off from Charité – Universitätsmedizin Berlin and the Berlin Institute of Health, is pioneering computational pathology for pharmaceutical research and diagnostics. Its proprietary “Explainable AI” platform draws on …
To the complete profileof Aignostics
Reactive Robotics is a leading healthcare startup dedicated to developing innovative technologies and solutions for the healthcare industry. The company is on a mission to revolutionize healthcare by integrating technology …
To the complete profileof Reactive Robotics
Hapila’s counter-current crystallisation process provides a cost effective procedure for purification of active pharmaceutical ingredients, completed by experience in synthesis and particle design.
To the complete profileof HAPILA
Pantherna Therapeutics is a privately-held biopharmaceutical company developing first-in-class therapeutics for vascular diseases. Pantherna’s innovative technology platform is based on advanced nanoparticles for the delivery and expression of therapeutic mRNA …
To the complete profileof Pantherna Therapeutics
mo:re has developed a groundbreaking lab platform, combining automation and software for planning, executing, and analysis of cell culture studies. The user-friendly platform aims to simplify cell culture, making organoids …
To the complete profileof mo:re
Exit
Modern therapeutic approaches face the challenge to combine efficacy, low undesired side effects and reasonable pricing. Therefore, drug substances become more and more complex, therapies become more personalized while overall …
To the complete profileof Belyntic
Biograil is a Danish start-up using injection molding to manufacture a device contained in a standard size capsule able to deliver active substances into the gastrointestinal wall. The Biograil device …
To the complete profileof Biograil
Exit
Sonormed is focused on digital medical products and builds the appropriate audiological infrastructure to adress the potential that large numbers of unserviced hearing damages, among them tinnitus, provide worldwide and …
To the complete profileof Sonormed
oncgnostics develops – based on proprietary epigenetic biomarkers – highly reliable molecular in-vitro diagnostic (IVD) tests for screening, follow-up care and therapeutic decisions in oncology.
To the complete profileof oncgnostics
Mosanna is a Swiss Biotech company based in Basel with a commitment to improving patient outcomes and quality of life in high unmet need diseases, applying a precision medicine approach. …
To the complete profileof Mosanna
Smarterials Technology GmbH is a young MedTech company with high competence in the fields of inorganic chemistry, surface functionalization and process technology. The company was founded by two material scientists …
To the complete profileof Smarterials Technology